Karolinska Development AB: Pharmanest Initiates Phase II Study of SHACT
STOCKHOLM--(BUSINESS WIRE)--Regulatory News: Today, Pharmanest AB announced that the first patient has been dosed in a randomized Phase II study of SHACT, a product developed for pain relief associated with intrauterine device (IUD) insertion. Karolinska Development AB (STO:KDEV) owns 58.9 percent of Pharmanest.